{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05607719",
            "orgStudyIdInfo": {
                "id": "20220347"
            },
            "organization": {
                "fullName": "University of Miami",
                "class": "OTHER"
            },
            "briefTitle": "Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD",
            "officialTitle": "The Effect of Inhaled Corticosteroids (ICS) Adjunct Therapy on Pulmonary Vascular Endothelial Function in Chronic Obstructive Pulmonary Disease (COPD): Comparison of Two Standard Treatments (NCT05607719",
            "therapeuticArea": [
                "Respiratory"
            ],
            "study": "inhaled-corticosteroids-ics-on-pulmonary-endothelial-function-in-copd"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-12",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-04-11",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-01-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-04-30",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-11-02",
            "studyFirstSubmitQcDate": "2022-11-02",
            "studyFirstPostDateStruct": {
                "date": "2022-11-07",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-12-14",
            "lastUpdatePostDateStruct": {
                "date": "2023-12-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Adam Wanner",
                "investigatorTitle": "Professor of Medicine",
                "investigatorAffiliation": "University of Miami"
            },
            "leadSponsor": {
                "name": "University of Miami",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "AstraZeneca",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The study objective is to determine whether an ICS added for 4 weeks to a baseline treatment with a Long-Acting Beta-adrenergic Agonist (LABA) and Long-Acting Muscarinic Antagonist (LAMA) combination improves pulmonary vascular endothelial function as assessed by the vasodilator response to inhaled albuterol (endothelium-dependent vasodilation) in stable COPD patients treated with a LABA/LAMA without an ICS for at least one month."
        },
        "conditionsModule": {
            "conditions": [
                "Chronic Obstructive Pulmonary Disease"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "CROSSOVER",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Bretzri followed by Bevespi Group",
                    "type": "EXPERIMENTAL",
                    "description": "Participants in this group will receive Bretzri for 4-weeks followed by 8-weeks of Bevespi.",
                    "interventionNames": [
                        "Drug: Bevespi",
                        "Drug: Bretzri"
                    ]
                },
                {
                    "label": "Bevespi followed by Bretzri Group",
                    "type": "EXPERIMENTAL",
                    "description": "Participants in this group will receive Bevespi for 8-weeks followed by 4-weeks of Bretzri.",
                    "interventionNames": [
                        "Drug: Bevespi",
                        "Drug: Bretzri"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Bevespi",
                    "description": "Two puffs twice a day",
                    "armGroupLabels": [
                        "Bevespi followed by Bretzri Group",
                        "Bretzri followed by Bevespi Group"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Bretzri",
                    "description": "Two puffs twice a day",
                    "armGroupLabels": [
                        "Bevespi followed by Bretzri Group",
                        "Bretzri followed by Bevespi Group"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Albuterol induced percent change in pulmonary vascular resistance (PVR)",
                    "description": "Echocardiographic assessment of PVR before and after inhalation of 180 \u03bcg albuterol as a test of endothelial function",
                    "timeFrame": "baseline to 15 minutes post inhalation"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Albuterol induced absolute change in PVR",
                    "description": "Echocardiographic assessment of PVR before and after inhalation of 180 \u03bcg albuterol as a test of endothelial function",
                    "timeFrame": "baseline, up to 45 minutes post inhalation"
                },
                {
                    "measure": "Percent change in FEV1",
                    "description": "Percent change in FEV1 will be measured using spirometry",
                    "timeFrame": "baseline to 15 minutes post inhalation"
                },
                {
                    "measure": "Change in oxygen saturation",
                    "description": "Change in oxygen saturation measured by pulse oximetry",
                    "timeFrame": "baseline, up to 45 minutes post inhalation"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* physician diagnosis of COPD\n* former smoking history of more than 10 pack-years\n* baseline post-bronchodilator one-second forced expiratory volume (FEV1) 50-80% of predicted, baseline FEV1 and forced vital capacity (FVC) ratio \\<0.7\n* males and females, 40-80 years of age\n* regular use of a LAMA/LABA drug regimen for at least a month\n\nExclusion Criteria:\n\n* women of childbearing potential who do not use accepted birth- control measures\n* pregnant and breast-feeding women\n* respiratory infection within 4 weeks of a test day\n* a Corona Virus Disease (COVID) vaccination \\<3 months prior to study entry\n* ICS use (within 4 weeks of study entry)\n* ICS hypersensitivity\n* albuterol intolerance\n* use of beta-blocker medication (oral and ophthalmic)\n* use of systemic glucocorticosteroid medication within 6 wk prior to the screening visit\n* an acute COPD exacerbation within 6 wk of the screening day (defined as a need for antibiotic or systemic glucocorticoid therapy or emergency department (ED) visit/hospitalization)\n* current smoking or vaping tobacco or other products\n* Oxygen (O2) saturation of \\<90% at-rest breathing room air\n* Long-term oxygen therapy (LTOT) required at rest\n* regular use of pulmonary vasodilators\n* systemic arterial systolic pressure \\>150 mmHg and diastolic pressure \\>100 mmHg on the test day\n* a \\>40mmHg right ventricular systolic pressure (RVSP) by prior echocardiography\n* a documented COVID infection within 4 weeks of the screening day\n* Regular use of home oxygen at rest\n* Physician diagnosis of obesity hypoventilation syndrome",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "40 Years",
            "maximumAge": "80 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Adam Wanner, MD",
                    "role": "CONTACT",
                    "phone": "(305) 243-2568",
                    "email": "awanner@med.miami.edu"
                },
                {
                    "name": "Jennifer Biondo",
                    "role": "CONTACT",
                    "phone": "(305) 243-2568",
                    "email": "jnb184@miami.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Adam Wanner, MD",
                    "affiliation": "University of Miami",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Miami",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33136",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jennifer Biondo",
                            "role": "CONTACT",
                            "phone": "305-243-2568",
                            "email": "jnb184@miami.edu"
                        },
                        {
                            "name": "Adam Wanner, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Barry Hurtwitz, PhD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000008173",
                    "term": "Lung Diseases, Obstructive"
                },
                {
                    "id": "D000029424",
                    "term": "Pulmonary Disease, Chronic Obstructive"
                }
            ],
            "ancestors": [
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000002908",
                    "term": "Chronic Disease"
                },
                {
                    "id": "D000020969",
                    "term": "Disease Attributes"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "asFound": "Pulmonary Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11170",
                    "name": "Lung Diseases, Obstructive",
                    "asFound": "Obstructive Pulmonary Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M23449",
                    "name": "Pulmonary Disease, Chronic Obstructive",
                    "asFound": "Chronic Obstructive Pulmonary Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27137",
                    "name": "Respiratory Aspiration",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6147",
                    "name": "Chronic Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "M22700",
                    "name": "Disease Attributes",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}